About: A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial
Creator	Wang, Tao Zheng, Zhishui Zhao, Yang Hu, Ke Lan, Ke Zhao, Dong Li, Honglin Zhang, Yunting Li, • Xu, • Wang, Mengmei Zeng, Shaolin
Source	Medline; PMC
abstract	We recently reported that inhibitors against human dihydroorotate dehydrogenase (DHODH) have broad-spectrum antiviral activities including their inhibitory efficacies on SARS-CoV-2 replication in infected cells. However, there are limited data from clinical studies to prove the application of DHODH inhibitors in Coronavirus disease 2019 (COVID-19) patients. In the present study, we evaluated Leflunomide, an approved DHODH inhibitor widely used as a modest immune regulator to treat autoimmune diseases, in treating COVID-19 disease with a small-scale of patients. Cases of 10 laboratory-confirmed COVID-19 patients of moderate type with obvious opacity in the lung were included. Five of the patients were treated with Leflunomide, and another five were treated as blank controls without a placebo. All the patients accepted standard supportive treatment for COVID-19. The patients given Leflunomide had a shorter viral shedding time (median of 5 days) than the controls (median of 11 days, P = 0.046). The patients given Leflunomide also showed a significant reduction in C-reactive protein levels, indicating that immunopathological inflammation was well controlled. No obvious adverse effects were observed in Leflunomide-treated patients, and they all discharged from the hospital faster than controls. This preliminary study on a small-scale compassionate use of Leflunomide provides clues for further understanding of Leflunomide as a potential antiviral drug against COVID-19.
has issue date	2020-07-21(xsd:dateTime)
bibo:doi	10.1007/s12250-020-00258-7
bibo:pmid	32696396
has license	no-cc
sha1sum (hex)	fcd53a787e41de342a55f8cd7d918a0da90f5561
schema:url	https://doi.org/10.1007/s12250-020-00258-7
resource representing a document's title	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial
has PubMed Central identifier	PMC7371831
has PubMed identifier	32696396
schema:publication	Virol Sin
resource representing a document's body	covid:fcd53a787e41de342a55f8cd7d918a0da90f5561#body_text
is schema:about of	named entity 'application' named entity 'broad-spectrum' named entity 'treat' named entity 'controls' named entity 'discharged' named entity 'inhibitors' named entity 'clues' named entity 'patients' named entity 'regulator' named entity 'observed' named entity 'activities' named entity 'supportive treatment' named entity 'clinical studies' named entity 'inhibitors' named entity 'opacity' named entity 'Medication' named entity 'Leflunomide' named entity 'viral shedding' named entity 'placebo' named entity 'efficacies' named entity 'Coronavirus disease 2019' named entity 'C-reactive protein' named entity 'Leflunomide' named entity 'autoimmune diseases' named entity 'COVID-19' named entity 'Controlled Clinical Trial' named entity 'Leflunomide' named entity 'Leflunomide' named entity 'Favipiravir' named entity 'chloroquine' named entity 'Leflunomide' named entity 'drug treatment' named entity 'drug development' named entity 'SARS-CoV-2' named entity 'side-effect' named entity 'COVID-19' named entity 'treatment group' named entity 'placebo' named entity 'ARAVA' named entity 'clinical outcomes' named entity 'interquartile range' named entity 'pyrimidine' named entity 'CRP' named entity 'lung' named entity 'Grein' named entity 'CT imaging' named entity 'infection' named entity 'drug target' named entity 'Teriflunomide' named entity 'C-reactive protein' named entity 'clinical trials' named entity 'virus' named entity 'contraception' named entity 'adverse effects' named entity 'hydroxychloroquine' named entity 'Leflunomide' named entity 'viral shedding' named entity 'WHO' named entity 'Leflunomide' named entity 'COVID-19' named entity 'COVID-19' named entity 'Yang Zhao' named entity 'white blood cell' named entity 'Cefoperazone' named entity 'treatment group' named entity 'antipyretic' named entity 'drug targets' named entity 'Leflunomide' named entity 'lymphocytes' named entity 'immune cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software